All sponsors

MedImmune LLC $AZN

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS5
PHASE 3 / 2-30
RECRUITING0
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO60%

Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +7.8 months). See all sponsors →

Open MedImmune LLC on the live radar map → 📅 $AZN readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Tremelimumab
NCT01843374
P2Active, not recruitingUnresectable Pleural or Peritoneal Malignant Mesothelioma5712016-01-24 (+8 mo)
Tremelimumab
NCT02519348
P2Active, not recruitingHepatocellular Carcinoma4332020-11-06 (+20 mo)
Oleclumab
NCT03381274
P1/2Active, not recruitingCarcinoma, Non-Small-Cell Lung432021-05-24 (-6 mo)
Monalizumab
NCT02671435
P1/2Active, not recruitingAdvanced Solid Tumors3832021-10-26 (+23 mo)
Durvalumab
NCT04068610
P1/2Active, not recruitingMetastatic Microsatellite-stable Colorectal Cancer612022-10-10 (-16 mo)